



ROCKSHIELD CAPITAL PROVIDES MEDTECH INVESTMENT PORTFOLIO UPDATE

Vancouver, British Columbia, June 6, 2018 - Rockshield Capital Corp. (CSE:RKS), (US:RKSCF), (FSE:6BC) (“Rockshield” or the “Company”) is pleased to provide an update on the Company’s medical technology investment portfolio.

Rockshield Capital has acquired an eclectic mix of investments focused on high growth sectors and supporting strong management teams. A key portion of our investment portfolio has been in the medical technology sector where we have backed two industry leading companies.

Helius Medical Technologies Inc.

Helius Medical Technologies Inc. (“Helius”) has reached a major milestone in its existence with the listing and trading of its common shares on April 11, 2018 on the Nasdaq Capital Market. Concurrent with the listing Helius completed a US \$16,000,000 financing at a price of US \$7.47 per unit.

Helius is a neurotech company focused on neurological wellness. The company’s mission is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. Helius’ first product in development, the Portable Neuromodulation Stimulator (“PoNS”), is an investigational, non-invasive, medical device designed for the treatment of neurological symptoms caused by disease or trauma.

Rockshield was an early supporter and has been a long-term shareholder of Helius, currently holding 263,800 shares.

Cognetivity Neurosciences Ltd.

On March 3, 2018 Cognetivity Neurosciences Ltd. (“Cognetivity”) commenced trading on the CSE under the symbol “CGN”. Cognetivity is a technology company developing a cognitive testing platform, the Integrated Cognithlive Assessment (“IAC”), for use in medical and commercial environments. Cognetivity’s ICA uses artificial intelligence and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large areas of the brain, potentially allowing early diagnosis of dementia. Cognetivity aims to develop the ICA through planned clinical studies to the market in North America and Europe.

More recently, Cognetivity announced it won the prestigious AXA Health Tech & You challenge in the “Innovations in the Early Diagnosis of Dementia” category. The winning Cognetivity platform involves a five-minute ICA test that looks for the earliest signs of impairment by testing the performance of large areas of the brain. The ICA test is easy to administer and its artificial intelligence engine can learn as it gathers new data to improve its ability to diagnose. As well as having the potential to be a highly effective dementia screening tool, the ICA test can also be used for remote monitoring of the progression of diseases and measuring the effectiveness of treatments.

Rockshield was an early private seed investor and currently owns 2,000,000 shares at a cost of \$0.25 per share.

Dave Doherty, President and CEO said *“We are very pleased with the continued advancement and success of these two leading healthcare technology companies. Helius’ listing on the NASDAQ is a major achievement for any company and in particular helps generate greater awareness given the much larger and more developed healthcare technology market in the US. As well we are very pleased to see Cognentivity complete its listing and are excited at the potential of this award winning technology.”*

ROCKSHIELD CAPITAL CORP.

Rockshield is an actively managed venture capital fund and merchant bank, focused on small cap high growth companies. Rockshield’s management team has been seed financing and investing in early stage venture companies for over the past 20 years and performs extensive due diligence as it looks to build a portfolio of opportunistic investments with the aim of generating superior long-term returns while managing risks. Leveraging the vast professional network and experience of the management team, Rockshield has early access to private and public deals and reviews hundreds of deals a year selecting only those with the best potential returns.

For further information regarding Rockshield, see Rockshield’s disclosure documents on SEDAR at www.sedar.com.

The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.

CONTACT INFORMATION

Rockshield Capital Corp.
Dave Doherty
President & CEO
dave@rockshield.ca

Dan Sorger
Director
dan@rockshield.ca